The proposed targeting of LAG-3 in immunotherapies has taken many forms, including (i) the delivery of soluble dimeric LAG-3 as an adjuvant therapy [15], (ii) the antibody blockade of LAG-3 interactions with its ligand(s) in cancer which has also been combined with an anti-Programmed Cell Death Protein 1 (PD-1) targeting therapy [16], (iii) antibody-mediated depletion of LAG-3+ cells in autoimmunity [17] and (iv) modulation of LAG-3 expression through small molecule targeting of Glycogen synthase kinase-3 (GSK-3) in cancer [18]. This evidence concerns the gene PDCD1 and Autoimmunity.